相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel Designs and End Points for Phase II Clinical Trials
Alex A. Adjei et al.
CLINICAL CANCER RESEARCH (2009)
Effective Incorporation of Biomarkers into Phase II Trials
Lisa M. McShane et al.
CLINICAL CANCER RESEARCH (2009)
Randomized Phase II Designs
Larry Rubinstein et al.
CLINICAL CANCER RESEARCH (2009)
Optimising the design of phase II oncology trials: The importance of randomisation
Mark J. Ratain et al.
EUROPEAN JOURNAL OF CANCER (2009)
Comparison of Power Between Randomized Discontinuation Design and Upfront Randomization Design on Progression-Free Survival
Pingfu Fu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial
Axel Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model
Rashmi Chugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trials in Journal of Clinical Oncology
Stephen A. Cannistra
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
An adjustment for patient heterogeneity in the design of two-stage phase II trials
Richard Sposto et al.
STATISTICS IN MEDICINE (2009)
Bayesian adaptive design for targeted therapy development in lung cancer - a step toward personalized medicine
Xian Zhou et al.
CLINICAL TRIALS (2008)
Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)
Christopher M. Booth et al.
EUROPEAN JOURNAL OF CANCER (2008)
Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III
Robert H. El-Maraghi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II stopping rules that employ response rates and early progression
John R. Goffin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Analysis of phase II studies on targeted agents and subsequent phase III trials: What are the predictors for success?
John K. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Tomasz Burzykowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The lessons of GIST - PET and PET/CT: A new paradigm for imaging
Annick D. Van den Abbeele
ONCOLOGIST (2008)
Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer
Theodore G. Karrison et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
Robert G. Maki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
We should desist using RECIST, at least in GIST
Robert S. Benjamin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Practical Bayesian adaptive randomisation in clinical trials
Peter F. Thall et al.
EUROPEAN JOURNAL OF CANCER (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Progression-free survival rate as primary end point for phase II cancer clinical trials: Application to mesothelioma - The EORTC Lung Cancer Group
Julie Francart et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bayesian clinical trials
DA Berry
NATURE REVIEWS DRUG DISCOVERY (2006)
Design issues of randomized phase II trials and a proposal for phase II screening trials
LV Rubinstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval
J Goffin et al.
CLINICAL CANCER RESEARCH (2005)
Evaluation of randomized discontinuation design
B Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Successful implementation of the Randomized discontinuation trial design: An application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma CALGB 69901
WM Stadler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Assessing surrogates as trial endpoints using mixed models
EL Korn et al.
STATISTICS IN MEDICINE (2005)
Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints
WB Capra
CONTROLLED CLINICAL TRIALS (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
FJ Giles et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies
B Morgan et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Seamlessly expanding a randomized phase II trial to phase III
LYT Inoue et al.
BIOMETRICS (2002)
Randomized discontinuation design: Application to cytostatic antineoplastic agents
GL Rosner et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Bayesian two-stage designs for phase II clinical trials
SB Tan et al.
STATISTICS IN MEDICINE (2002)
A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer
S Tan et al.
BRITISH JOURNAL OF CANCER (2002)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
M Van Glabbeke et al.
EUROPEAN JOURNAL OF CANCER (2002)
A Bayesian decision approach for sample size determination in phase II trials
DHY Leung et al.
BIOMETRICS (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint
R Mick et al.
CONTROLLED CLINICAL TRIALS (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
